<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37111040</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>A Glutamate Scavenging Protocol Combined with Deanna Protocol in SOD1-G93A Mouse Model of ALS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1821</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu15081821</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive disease of neuronal degeneration in the motor cortex, brainstem, and spinal cord, resulting in impaired motor function and premature demise as a result of insufficient respiratory drive. ALS is associated with dysfunctions in neurons, neuroglia, muscle cells, energy metabolism, and glutamate balance. Currently, there is not a widely accepted, effective treatment for this condition. Prior work from our lab has demonstrated the efficacy of supplemental nutrition with the Deanna Protocol (DP). In the present study, we tested the effects of three different treatments in a mouse model of ALS. These treatments were the DP alone, a glutamate scavenging protocol (GSP) alone, and a combination of the two treatments. Outcome measures included body weight, food intake, behavioral assessments, neurological score, and lifespan. Compared to the control group, DP had a significantly slower decline in neurological score, strength, endurance, and coordination, with a trend toward increased lifespan despite a greater loss of weight. GSP had a significantly slower decline in neurological score, strength, endurance, and coordination, with a trend toward increased lifespan. DP+GSP had a significantly slower decline in neurological score with a trend toward increased lifespan, despite a greater loss of weight. While each of the treatment groups fared better than the control group, the combination of the DP+GSP was not better than either of the individual treatments. We conclude that the beneficial effects of the DP and the GSP in this ALS mouse model are distinct, and appear to offer no additional benefit when combined.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Christopher Q</ForeName><Initials>CQ</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landon</LastName><ForeName>Carol S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeBlasi</LastName><ForeName>Janine M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koutnik</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Healthspan, Resilience and Performance, Florida Institute for Human and Machine Cognition, 40 S Alcaniz St, Pensacola, FL 32502, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ari</LastName><ForeName>Csilla</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8677-823X</Identifier><AffiliationInfo><Affiliation>Department of Psychology, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ketone Technologies LLC, 12608 Forest Hills Dr, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Dominic P</ForeName><Initials>DP</Initials><Identifier Source="ORCID">0000-0001-9652-181X</Identifier><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Laboratory of Metabolic Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ketone Technologies LLC, 12608 Forest Hills Dr, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>111990</GrantID><Agency>Winning the Fight Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CoQ10</Keyword><Keyword MajorTopicYN="N">Deanna Protocol</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">blood glutamate scavengers</Keyword><Keyword MajorTopicYN="N">medium chain triglycerides</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">oxaloacetic acid</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37111040</ArticleId><ArticleId IdType="pmc">PMC10141074</ArticleId><ArticleId IdType="doi">10.3390/nu15081821</ArticleId><ArticleId IdType="pii">nu15081821</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbott E.O., Malek A.M., Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb. Clin. Neurol. 2016;138:225&#x2013;238. doi: 10.1016/B978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Mi J.D., Henderson R.D., McCombe P.A., Steyn F.J. Exploring targets and therapies for amyotrophic lateral sclerosis: Current insights into dietary interventions. Degener. Neurol. Neuromuscul. Dis. 2017;7:95&#x2013;108. doi: 10.2147/DNND.S120607.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S120607</ArticleId><ArticleId IdType="pmc">PMC6053104</ArticleId><ArticleId IdType="pubmed">30050381</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Horton D.K., Mitsumoto H. Potential Environmental Factors in Amyotrophic Lateral Sclerosis. Neurol. Clin. 2015;33:877&#x2013;888. doi: 10.1016/j.ncl.2015.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.009</ArticleId><ArticleId IdType="pmc">PMC4646848</ArticleId><ArticleId IdType="pubmed">26515627</ArticleId></ArticleIdList></Reference><Reference><Citation>Halperin J.J., Kaplan G.P., Brazinsky S., Tsai T.F., Cheng T., Ironside A., Wu P., Delfiner J., Golightly M., Brown R.H., et al. Immunologic reactivity against Borrelia burgdorferi in patients with motor neuron disease. Arch. Neurol. 1990;47:586&#x2013;594. doi: 10.1001/archneur.1990.00530050110021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1990.00530050110021</ArticleId><ArticleId IdType="pubmed">2334308</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y.C., Feuer R., Cashman N., Luo H. Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis? Front. Mol. Neurosci. 2018;11:63. doi: 10.3389/fnmol.2018.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00063</ArticleId><ArticleId IdType="pmc">PMC5857577</ArticleId><ArticleId IdType="pubmed">29593492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffo P., Perrone B., Conforti F.L. SOD-1 Variants in Amyotrophic Lateral Sclerosis: Systematic Re-Evaluation According to ACMG-AMP Guidelines. Genes. 2022;13:537. doi: 10.3390/genes13030537.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13030537</ArticleId><ArticleId IdType="pmc">PMC8955492</ArticleId><ArticleId IdType="pubmed">35328090</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice J.R., Gregory-Evans C.Y., Shaw C.A. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural. Regen. Res. 2018;13:2050&#x2013;2054. doi: 10.4103/1673-5374.241445.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.241445</ArticleId><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004;27:723&#x2013;749. doi: 10.1146/annurev.neuro.27.070203.144244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O., Bordoni M., Diamanti L., Sproviero D., Gagliardi S., Cereda C. SOD1 in Amyotrophic Lateral Sclerosis: "Ambivalent" Behavior Connected to the Disease. Int. J. Mol. Sci. 2018;19:1345. doi: 10.3390/ijms19051345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051345</ArticleId><ArticleId IdType="pmc">PMC5983710</ArticleId><ArticleId IdType="pubmed">29751510</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S., Vande Velde C., Cleveland D.W. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59. doi: 10.1016/j.neuron.2006.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Bouchard J.P., Duquette P., Eisen A., Gelinas D., Harati Y., Munsat T.L., Powe L., Rothstein J., Salzman P., et al. Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S86&#x2013;S90, discussion S90&#x2013;S92. doi: 10.1212/WNL.47.4_Suppl_2.86S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.4_Suppl_2.86S</ArticleId><ArticleId IdType="pubmed">8858057</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:S233&#x2013;S241. doi: 10.1212/WNL.47.6_Suppl_4.233S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.233S</ArticleId><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh J.Y., Kim D.K., Hwang J.Y., Kim Y.H., Seo J.H. Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons. J. Neurochem. 1999;72:716&#x2013;723. doi: 10.1046/j.1471-4159.1999.0720716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.0720716.x</ArticleId><ArticleId IdType="pubmed">9930745</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibowitz A., Boyko M., Shapira Y., Zlotnik A. Blood glutamate scavenging: Insight into neuroprotection. Int. J. Mol. Sci. 2012;13:10041&#x2013;10066. doi: 10.3390/ijms130810041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms130810041</ArticleId><ArticleId IdType="pmc">PMC3431845</ArticleId><ArticleId IdType="pubmed">22949847</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyko M., Stepensky D., Gruenbaum B.F., Gruenbaum S.E., Melamed I., Ohayon S., Glazer M., Shapira Y., Zlotnik A. Pharmacokinetics of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase and their blood glutamate-lowering activity in naive rats. Neurochem. Res. 2012;37:2198&#x2013;2205. doi: 10.1007/s11064-012-0843-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-012-0843-9</ArticleId><ArticleId IdType="pubmed">22846966</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Mato M., Ramos-Cabrer P., Sobrino T., Blanco M., Ruban A., Mirelman D., Menendez P., Castillo J., Campos F. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis. 2014;5:e992. doi: 10.1038/cddis.2013.507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.507</ArticleId><ArticleId IdType="pmc">PMC4040715</ArticleId><ArticleId IdType="pubmed">24407245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruban A., Berkutzki T., Cooper I., Mohar B., Teichberg V.I. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest. New Drugs. 2012;30:2226&#x2013;2235. doi: 10.1007/s10637-012-9794-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-012-9794-x</ArticleId><ArticleId IdType="pmc">PMC3484283</ArticleId><ArticleId IdType="pubmed">22392507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruban A., Malina K.C., Cooper I., Graubardt N., Babakin L., Jona G., Teichberg V.I. Combined Treatment of an Amyotrophic Lateral Sclerosis Rat Model with Recombinant GOT1 and Oxaloacetic Acid: A Novel Neuroprotective Treatment. Neurodegener. Dis. 2015;15:233&#x2013;242. doi: 10.1159/000382034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000382034</ArticleId><ArticleId IdType="pubmed">26113413</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams D.S., Cash A., Hamadani L., Diemer T. Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK/FOXO-dependent pathway. Aging Cell. 2009;8:765&#x2013;768. doi: 10.1111/j.1474-9726.2009.00527.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2009.00527.x</ArticleId><ArticleId IdType="pmc">PMC2988682</ArticleId><ArticleId IdType="pubmed">19793063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ari C., Poff A.M., Held H.E., Landon C.S., Goldhagen C.R., Mavromates N., D&#x2019;Agostino D.P. Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS ONE. 2014;9:e103526. doi: 10.1371/journal.pone.0103526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0103526</ArticleId><ArticleId IdType="pmc">PMC4111621</ArticleId><ArticleId IdType="pubmed">25061944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ari C., Canfield C.E., Copes N., Poff A.M., Fiorelli T.N., Landon C.S., Goldhagen C.R., Mavromates N., D&#x2019;Agostino D.P. Biochemical alterations in Amyotrophic Lateral Sclerosis (ALS) Mouse Model resulted from the Deanna Protocol Supplement Complex. Metabolomics. 2017;13:55. doi: 10.1007/s11306-017-1183-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-017-1183-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavado A., Guo X., Smith A.S., Akanda N., Martin C., Cai Y., Elbrecht D., Tran M., Bryant J.P., Colon A., et al. Evaluation of Holistic Treatment for ALS Reveals Possible Mechanism and Therapeutic Potential. Int. J. Pharm. Pharm. Res. 2017;11:348&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6326589</ArticleId><ArticleId IdType="pubmed">30637316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral. Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Truong T.C., Vallat J.M., Sautereau D., Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059&#x2013;1063. doi: 10.1212/WNL.53.5.1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.5.1059</ArticleId><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.F., Ludolph A.C., Loeffler J.P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivello M., Hogg M.C., Jirstrom E., Halang L., Woods I., Rayner M., Coughlan K.S., Lewandowski S.A., Prehn J.H.M. Vascular regression precedes motor neuron loss in the FUS (1-359) ALS mouse model. Dis. Model. Mech. 2019;12:dmm040238. doi: 10.1242/dmm.040238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.040238</ArticleId><ArticleId IdType="pmc">PMC6737946</ArticleId><ArticleId IdType="pubmed">31383794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Ryu H., Kowall N.W. Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice. Biochem. Biophys. Res. Commun. 2009;384:524&#x2013;529. doi: 10.1016/j.bbrc.2009.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.05.015</ArticleId><ArticleId IdType="pmc">PMC2744197</ArticleId><ArticleId IdType="pubmed">19427829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuma I., Stuehr D.J., Gross S.S., Nathan C., Levi R. Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. USA. 1988;85:8664&#x2013;8667. doi: 10.1073/pnas.85.22.8664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.22.8664</ArticleId><ArticleId IdType="pmc">PMC282520</ArticleId><ArticleId IdType="pubmed">3263652</ArticleId></ArticleIdList></Reference><Reference><Citation>Boger R.H., Bode-Boger S.M., Thiele W., Creutzig A., Alexander K., Frolich J.C. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. 1998;32:1336&#x2013;1344. doi: 10.1016/S0735-1097(98)00375-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(98)00375-1</ArticleId><ArticleId IdType="pubmed">9809945</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris C.R., Kuypers F.A., Lavrisha L., Ansari M., Sweeters N., Stewart M., Gildengorin G., Neumayr L., Vichinsky E.P. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98:1375&#x2013;1382. doi: 10.3324/haematol.2013.086637.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2013.086637</ArticleId><ArticleId IdType="pmc">PMC3762093</ArticleId><ArticleId IdType="pubmed">23645695</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade F., Rodriguez-Soriano J., Prieto J.A., Elorz J., Aguirre M., Ariceta G., Martin S., Sanjurjo P., Aldamiz-Echevarria L. The arginine-creatine pathway is disturbed in children and adolescents with renal transplants. Pediatr. Res. 2008;64:218&#x2013;222. doi: 10.1203/PDR.0b013e318176180e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e318176180e</ArticleId><ArticleId IdType="pubmed">18391841</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., De Bock K., Van Den Bosch L. Energy metabolism in ALS: An underappreciated opportunity? Acta Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Oudart H., Rene F., Gonzalez de Aguilar J.L., Loeffler J.P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. USA. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach A.C., Babayan V.K. Medium-chain triglycerides: An update. Am. J. Clin. Nutr. 1982;36:950&#x2013;962. doi: 10.1093/ajcn/36.5.950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/36.5.950</ArticleId><ArticleId IdType="pubmed">6814231</ArticleId></ArticleIdList></Reference><Reference><Citation>Crugnola V., Lamperti C., Lucchini V., Ronchi D., Peverelli L., Prelle A., Sciacco M., Bordoni A., Fassone E., Fortunato F., et al. Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch. Neurol. 2010;67:849&#x2013;854. doi: 10.1001/archneurol.2010.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.128</ArticleId><ArticleId IdType="pubmed">20625092</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA. 1998;95:8892&#x2013;8897. doi: 10.1073/pnas.95.15.8892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.15.8892</ArticleId><ArticleId IdType="pmc">PMC21173</ArticleId><ArticleId IdType="pubmed">9671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009;66:235&#x2013;244. doi: 10.1002/ana.21743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21743</ArticleId><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchetti J., Marino M., Papa S., Tortarolo M., Guiso G., Pozzi S., Bonetto V., Caccia S., Beghi E., Bendotti C., et al. A mouse model of familial ALS has increased CNS levels of endogenous ubiquinol9/10 and does not benefit from exogenous administration of ubiquinol10. PLoS ONE. 2013;8:e69540. doi: 10.1371/journal.pone.0069540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0069540</ArticleId><ArticleId IdType="pmc">PMC3720666</ArticleId><ArticleId IdType="pubmed">23936040</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Kiernan M.C., Swash M. Fasciculation in amyotrophic lateral sclerosis: Origin and pathophysiological relevance. J. Neurol. Neurosurg. Psychiatry. 2017;88:773&#x2013;779. doi: 10.1136/jnnp-2017-315574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315574</ArticleId><ArticleId IdType="pubmed">28490504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapin I. Phenibut (beta-phenyl-GABA): A tranquilizer and nootropic drug. CNS Drug Rev. 2001;7:471&#x2013;481. doi: 10.1111/j.1527-3458.2001.tb00211.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3458.2001.tb00211.x</ArticleId><ArticleId IdType="pmc">PMC6494145</ArticleId><ArticleId IdType="pubmed">11830761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers. Arch. 2010;460:525&#x2013;542. doi: 10.1007/s00424-010-0809-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-010-0809-1</ArticleId><ArticleId IdType="pubmed">20229265</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyko M., Gruenbaum S.E., Gruenbaum B.F., Shapira Y., Zlotnik A. Brain to blood glutamate scavenging as a novel therapeutic modality: A review. J. Neural. Transm. 2014;121:971&#x2013;979. doi: 10.1007/s00702-014-1181-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-014-1181-7</ArticleId><ArticleId IdType="pmc">PMC4382077</ArticleId><ArticleId IdType="pubmed">24623040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruban A., Mohar B., Jona G., Teichberg V.I. Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication. J. Cereb. Blood Flow Metab. 2014;34:221&#x2013;227. doi: 10.1038/jcbfm.2013.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2013.186</ArticleId><ArticleId IdType="pmc">PMC3915200</ArticleId><ArticleId IdType="pubmed">24149933</ArticleId></ArticleIdList></Reference><Reference><Citation>Group A.U., Fournier C., Bedlack B., Hardiman O., Heiman-Patterson T., Gutmann L., Bromberg M., Ostrow L., Carter G., Kabashi E., et al. ALS Untangled No. 20: The Deanna protocol. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 2013;14:319&#x2013;323. doi: 10.3109/21678421.2013.788405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.788405</ArticleId><ArticleId IdType="pubmed">23638638</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins H.M., Harris J.L., Carl S.M., E L., Lu J., Eva Selfridge J., Roy N., Hutfles L., Koppel S., Morris J., et al. Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum. Mol. Genet. 2014;23:6528&#x2013;6541. doi: 10.1093/hmg/ddu371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu371</ArticleId><ArticleId IdType="pmc">PMC4271074</ArticleId><ArticleId IdType="pubmed">25027327</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto H.A., Mohanan P.V. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol. Lett. 2003;143:115&#x2013;122. doi: 10.1016/S0378-4274(03)00114-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-4274(03)00114-0</ArticleId><ArticleId IdType="pubmed">12749815</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., He L., Yao K. The Antioxidative Function of Alpha-Ketoglutarate and Its Applications. Biomed. Res. Int. 2018;2018:3408467. doi: 10.1155/2018/3408467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3408467</ArticleId><ArticleId IdType="pmc">PMC5884300</ArticleId><ArticleId IdType="pubmed">29750149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N., Yang M., Gaur U., Xu H., Yao Y., Li D. Alpha-Ketoglutarate: Physiological Functions and Applications. Biomol. Ther. 2016;24:1&#x2013;8. doi: 10.4062/biomolther.2015.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2015.078</ArticleId><ArticleId IdType="pmc">PMC4703346</ArticleId><ArticleId IdType="pubmed">26759695</ArticleId></ArticleIdList></Reference><Reference><Citation>Genton L., Viatte V., Janssens J.P., Heritier A.C., Pichard C. Nutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patients. Clin. Nutr. 2011;30:553&#x2013;559. doi: 10.1016/j.clnu.2011.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2011.06.004</ArticleId><ArticleId IdType="pubmed">21798636</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm T., Maier A., Wicks P., Lang D., Linke P., Munch C., Steinfurth L., Meyer R., Meyer T. Severe loss of appetite in amyotrophic lateral sclerosis patients: Online self-assessment study. Interact. J. Med. Res. 2013;2:e8. doi: 10.2196/ijmr.2463.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/ijmr.2463</ArticleId><ArticleId IdType="pmc">PMC3632382</ArticleId><ArticleId IdType="pubmed">23608722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Murthy S.B., Wilson A.M., Qureshi S.U., Amro M.J., Wheaton M., Simpson E., Harati Y., Strutt A.M., York M.K., et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph. Lateral. Scler. 2010;11:542&#x2013;548. doi: 10.3109/17482968.2010.482592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.482592</ArticleId><ArticleId IdType="pubmed">20500116</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Deng J., Jaffa M., Cudkowicz M.E., Wills A.M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Lange D.J., Voustianiouk A., MacGrogan D., Ho L., Suh J., Humala N., Thiyagarajan M., Wang J., Pasinetti G.M. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29. doi: 10.1186/1471-2202-7-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-7-29</ArticleId><ArticleId IdType="pmc">PMC1488864</ArticleId><ArticleId IdType="pubmed">16584562</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Loeffler J.P. Neuromuscular junction destruction during amyotrophic lateral sclerosis: Insights from transgenic models. Curr. Opin. Pharmacol. 2009;9:341&#x2013;346. doi: 10.1016/j.coph.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2009.03.007</ArticleId><ArticleId IdType="pubmed">19386549</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio F.P., Carrasco M.A., Siao M.C., Maniatis T., Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 2007;10:608&#x2013;614. doi: 10.1038/nn1885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1885</ArticleId><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251&#x2013;253. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Boncompagni S., Belia S., Wannenes F., Nicoletti C., Del Prete Z., et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 2008;8:425&#x2013;436. doi: 10.1016/j.cmet.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.09.002</ArticleId><ArticleId IdType="pubmed">19046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musaro A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007;26:1&#x2013;13. doi: 10.1016/j.nbd.2006.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.12.015</ArticleId><ArticleId IdType="pubmed">17300945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>